Overview of Hydrocortison Jelfa

Hydrocortison Jelfa is a medicine containing the active ingredient Hydrocortisone, which is chemically identical to the natural hormone cortisol, classified as a powerful Corticosteroid, utilized to manage inflammation and modulate the body's immune responses.

Quick Facts	Description
Active Ingredient	Hydrocortisone (INN)
Pharmacological Class	Corticosteroid, Glucocorticoid
Form	Tablet, Cream, Ointment, Solution for Injection
Common Use	Hormone Replacement and Anti-inflammatory
Origin	Synthetic (pharmaceutical), Identical to natural Cortisol

What Type of Medicine is Hydrocortison Jelfa? (Identity and Class)

The medication utilizes Hydrocortisone (INN), which falls into the pharmacological class of Glucocorticoids, a subset of the larger Corticosteroid group. This substance is chemically identical to cortisol, the primary glucocorticoid hormone naturally synthesized by the human adrenal cortex. Hydrocortisone is crucial for regulating the body's response to stress, metabolism, and immune function. This regulatory role is why the drug is clinically recognized for stabilizing patients requiring hormone replacement. The preparation, often manufactured by Jelfa S.A., is a single-ingredient product prepared synthetically for therapeutic administration, ensuring purity and consistent potency across its multiple prescription-only forms.

Composition and Available Forms of Hydrocortisone (Substance and Delivery)

Composition centers on the Hydrocortisone active ingredient combined with a specific pharmaceutical base/vehicle designed to suit the intended therapeutic effect. These preparations allow the substance to be delivered via multiple routes of administration. Forms include oral tablets for systemic effects, creams or ointments for topical skin application, and sterile solutions for rapid intravenous or intramuscular injection. The drug's different forms, such as oral and parenteral (injectable), allow medical specialists flexibility in treating acute systemic conditions versus localized inflammatory sites.

What is the General Purpose of Hydrocortisone? (Action and Benefit)

The core purpose of Hydrocortisone is rooted in its ability to mimic natural hormones and exert potent anti-inflammatory and immunosuppressive effects. It achieves this by suppressing the release of substances in the body that cause inflammation. This action is essential for providing replacement therapy when a person has low levels of natural corticosteroids, a typical use scenario. Furthermore, its profound anti-inflammatory properties are recognized for generally alleviating symptoms associated with excessive inflammatory activity, such as that seen in certain allergic or autoimmune disorders.

Regulatory References

What side effects are possible with Hydrocortison Jelfa?

Possible side effects and safety information

The officially documented adverse effects of systemic Hydrocortisone are frequently categorized by the physiological system impacted. Many of the reported reactions are inherently tied to the medicine’s potent glucocorticoid activity, with risk generally increasing with higher doses and prolonged exposure.

System-Organ Class	Common Adverse Reactions (Label-Documented)
Metabolism & Endocrine	Weight gain, fluid retention, hypertension, and the development of Cushingoid features
Psychiatric	Mood disturbances (including anxiety and euphoria), or insomnia
Musculoskeletal	Potential for muscle weakness (myopathy) and osteoporosis (bone fragility)

The safety profile includes specific warnings regarding serious adverse reactions. These include the risk of severe infections (which the medicine may mask) and adrenal crisis (adrenocortical insufficiency), a potentially life-threatening reaction that can occur if the medicine is abruptly stopped after long-term use. The official regulatory labeling explicitly states that the potential for adrenal insufficiency can persist for months after therapy is discontinued.

Safety notes also address specific populations. Pediatric patients are noted to have the potential for growth retardation and developmental issues due to the risk of HPA axis suppression. Additionally, an enhanced effect of the medicine is officially documented in patients who have hypothyroidism or hepatic impairment (such as cirrhosis).

The medicine is formally contraindicated in individuals with systemic fungal infections. The profile further advises that long-term exposure is associated with an increased risk of specific ocular adverse effects, including glaucoma and posterior subcapsular cataracts.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Hydrocortisone overdose distinguishes between the outcomes of acute toxicity and the serious consequences of chronic exposure.

Acute overdose from massive ingestion is generally associated with low immediate toxicity. However, medical assessment is required to manage potential alterations in fluid balance and electrolyte levels that may occur. The primary systemic concern from excessive steroid exposure is the risk associated with prolonged, high-dose use (chronic overdose), which may lead to the development of characteristic Cushing’s syndrome manifestations, impacting multiple physiological systems.

Mandated Emergency Action Triggers

Urgent medical attention is required immediately if an individual exhibits severe manifestations documented in regulatory labeling. These officially recognized severe outcomes include convulsions (seizures) or heart rhythm disturbances (e.g., irregular pulse). Regulatory guidance mandates that emergency services be contacted without delay if the person collapses, is actively seizing, or cannot be awakened.

Management is defined as symptomatic and supportive treatment because no specific antidote is known for hydrocortisone overdose. Treatment for chronic excess requires a controlled, gradual reduction or complete withdrawal of the medication under continuous medical supervision. Special consideration for pediatric patients requires monitoring for potential adverse effects on normal growth and development and HPA axis function.

Therapeutic Uses of Hydrocortison Jelfa

What Hydrocortison Jelfa Treats: Main Uses and Benefits

Hydrocortison Jelfa is commonly used to help with conditions where the body does not produce enough natural cortisol, such as adrenocortical deficiency (including Addison's disease and congenital adrenal hyperplasia). This application focuses on addressing symptoms related to systemic imbalance and physiological strain. In situations where patients experience these conditions, this medication is commonly used as replacement therapy. The primary therapeutic use involves providing symptomatic support across therapeutic domains, including severe inflammatory and autoimmune conditions like rheumatoid arthritis and lupus, certain types of inflammatory bowel disease, and inflammatory or irritative allergic or dermatologic flare-ups.

The medication is relevant for easing symptoms that become more disruptive during these episodes and is applied across domains where additional symptomatic support is needed. It provides support that helps ease the overall symptom burden, assisting with maintaining functional stability and helping patients cope more steadily with symptom fluctuations, whether the distress is from profound joint swelling or intractable dermatitis.

Quick Fact: Relief for Inflammation
General Benefit	Easing symptoms related to physical discomfort and systemic imbalance.
Context of Use	Applied during phases when symptoms become more noticeable and supportive relief is needed.
Typical Symptoms	Swelling, pain, fatigue, and intense itching in episodic or fluctuating manifestations.

Regulatory References

FDA DailyMed overview of hydrocortisone indications

Eligibility and Restrictions for Use

This section details the official eligibility and non-eligibility rules for Hydrocortison Jelfa (hydrocortisone) based on government regulatory documentation. Eligibility is determined by absolute contraindications, patient age, and concurrent medical conditions.

Contraindicated Populations and Conditions

Classification	Who Cannot Use the Medicine
Absolute Contraindications	Patients with known hypersensitivity to hydrocortisone or its components. Patients with untreated systemic infections (including systemic fungal infections).
Topical Contraindications	Viral diseases (e.g., herpes, chickenpox), bacterial/fungal skin infections, rosacea, or ulcers in the treatment area.

Restrictions and Special Populations

Population Category	Eligibility Status
Age Groups	Use in children and adolescents requires caution and monitoring due to the risk of growth suppression; prolonged use in these groups is generally restricted.
Pregnancy and Lactation	Pregnancy status is typically classified as safety not established in controlled human studies, requiring use only when benefit justifies risk. The drug is present in breast milk; caution is advised, especially with high doses.
Comorbidity Limitations	Caution is mandatory for patients with conditions such as diabetes mellitus, hypertension, osteoporosis, tuberculosis, or gastrointestinal disorders (e.g., peptic ulceration), as the medication may exacerbate these states.

Regulatory information requires that use be carefully considered in patients with hepatic impairment.

What should I know about interactions with other medicines?

Hydrocortison Jelfa Interactions with other medicines and products

Interactions with Hydrocortison Jelfa (Hydrocortisone) are governed by the substance’s metabolism and its powerful pharmacological actions, as documented in regulatory information.

Formally Contraindicated Combinations

Co-administration is strictly contraindicated with Live or Live, Attenuated Vaccines when the corticosteroid is used in immunosuppressive doses. Use is also restricted in the presence of Systemic Fungal Infections.

Interactions Modifying Hydrocortisone Levels

Hydrocortisone is metabolized by the CYP3A4 enzyme, meaning co-administered medicines can significantly alter its concentration. Official labeling identifies two main groups:

Interacting Substance Type	Specific Agents Cited (Examples)	Effect on Hydrocortisone
Enzyme Inducers	Rifampicin, Carbamazepine, Phenytoin	Decreases exposure/effect (accelerated metabolism)
Enzyme Inhibitors	Ketoconazole, Ritonavir, Clarithromycin	Increases exposure/effect (slowed metabolism)

Pharmacodynamic and Other Interactions

Hydrocortisone has antagonistic effects on the action of Hypoglycaemic Agents (including Insulin) and Antihypertensives. It enhances the effect of Coumarin Anticoagulants and the hypokalaemic effects of Potassium-Depleting Diuretics. Concomitant use with Grapefruit Juice can also increase Hydrocortisone levels due to CYP3A4 inhibition.

Special caution is noted for patients with hepatic impairment and hypothyroidism, as decreased drug clearance can officially lead to an enhanced corticosteroid effect, making interactions more pronounced.

Mechanism of Action

Hydrocortison Jelfa functions as an agonist, mimicking endogenous glucocorticoids by binding to the intracellular glucocorticoid receptor (GR), a member of the nuclear receptor superfamily. Upon ligand binding, the activated GR complex dissociates from chaperone proteins and translocates to the cell nucleus.

Within the nucleus, the complex modulates gene transcription through two primary mechanistic pathways: transactivation and transrepression. Via transactivation, the complex binds to specific DNA sequences known as Glucocorticoid Response Elements (GREs), initiating the transcription of genes like those coding for annexin A1 (lipocortin-1). Transrepression occurs when the GR complex physically interferes with the activity of pro-inflammatory transcription factors, such as NF-κB and AP-1, suppressing the expression of genes encoding cytokines, chemokines, and other inflammatory mediators.

At a system-level physiological consequence, this genomic modulation leads to a net reduction in the circulating population and extravasation of key leukocytes (e.g., lymphocytes and eosinophils), while concurrently inhibiting the synthesis and release of critical inflammatory signaling molecules, thus modulating systemic physiological response.

Dosage and Administration Information

Hydrocortisone administration is structured to align with its purpose as either hormone replacement or as an anti-inflammatory agent.

Official Administration Routes and Dosing

The medicine is officially administered via Oral routes (tablets, granules) for systemic effects, or by Intravenous (IV) or Intramuscular (IM) injection for acute systemic needs. Topical preparations are used for external localized application.

Usage Context	Standard Dosing Principle	Frequency Pattern
Hormone Replacement	Daily dose typically in the 15 mg to 25 mg range.	Two to three times daily (divided doses), with the largest dose in the morning to mimic natural rhythm.
Anti-inflammatory Use	Initial oral doses range from 20 mg up to 240 mg daily.	Varies, with the goal being to gradually reduce the dose to the minimum effective amount.
Acute Crisis (IV/IM)	Immediate bolus of 100 mg; maintained at 200 mg over 24 hours by infusion or repeated injections.	Repeated every 4 to 6 hours for sustained high levels.

Administration Conditions and Procedural Rules

Oral Intake: Standard tablets may be taken with food or milk to help prevent stomach upset. Modified-release tablets must be swallowed whole and are often required to be taken on an empty stomach (e.g., 30 minutes before food). Oral granules must not be chewed or crushed.

Duration and Tapering: For long-term therapy, such as hormone replacement, use is typically lifelong. If systemic therapy is to be discontinued, the dose must be gradually reduced (tapered) to allow the body to adjust. Dose adjustments may also be required for pediatric patients based on body surface area or for older adults who require cautious titration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Hydrocortison Jelfa

The research into hydrocortisone, the active ingredient in Hydrocortison Jelfa, spans many decades and includes a diverse range of study types, reflecting its use in hormone replacement and in research contexts exploring inflammation. The evidence base describes the patterns and outcomes that have been observed so far in different patient groups.

Evidence for Use in Hormone Replacement Therapy

Research was studied for use in conditions where the body does not naturally produce enough cortisol, such as Addison's disease. Study designs include long-term observational cohort studies and retrospective registry analyses. Research examined how outcomes related to physiological strain or systemic imbalance evolved over time in observed patient populations.

The findings from these long-term studies describe patterns related to the maintenance of clinical stability and monitoring of long-term physiological metrics in these populations. What remains uncertain is the difficulty in identifying a single, ideal biochemical marker that reliably correlates with the patient's individual experience of well-being.

Evidence for Use in Acute, Severe Inflammatory Conditions

Hydrocortisone was studied for use in severe, life-threatening inflammatory states, such as septic shock. Research for this application was evaluated in multiple large, randomized controlled trials (RCTs) and subsequent analyses. The studies monitored critically ill adults who required intensive care support.

Researchers examined severe endpoints like measurement of all-cause outcomes and monitored outcomes related to the body's acute response, such as time to physiological stabilization. However, the findings across some of the key trials have been mixed, showing inconsistency in the reported measurement of outcomes.

What Remains Unclear or Under Research

Evidence highlights what is known and what is still uncertain across the research landscape. For chronic inflammatory uses, the research available often uses evidence from the entire corticosteroid class, meaning specific long-term data for hydrocortisone are not fully established. Furthermore, for adrenal hormone replacement, research continues to explore the impact of subtle differences in administration regimens on long-term metabolic health.

Key Studies & References Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

Frequently Asked Questions (FAQ)

Common questions about Hydrocortison Jelfa (FAQ)

Q: Is Hydrocortison Jelfa the same as other steroid creams?

Official documents describe hydrocortisone, the active ingredient, as a low-potency topical corticosteroid. The potency and strength of other steroid creams can vary significantly and are officially categorized into seven different groups.

This information indicates that the strength of Hydrocortison Jelfa may differ from that of other available steroid creams.

Q: Are the side effects of Hydrocortison Jelfa common?

According to regulatory product information, several systemic adverse effects are classified as common. This means that these effects are documented to occur in more than 1 in 100 people who use the medicine.

Official documentation notes that the prevalence and severity of reactions can vary based on factors such as dosage and duration of exposure.

Q: What happens if I stop using Hydrocortison Jelfa suddenly?

For systemic, long-term use, stopping the medication abruptly may cause symptoms associated with adrenal insufficiency, which can be severe. Official documents describe this potential consequence as dangerous, noting symptoms may include severe tiredness, body aches, weakness, and dizziness.

Regulatory sources indicate that a gradual dose reduction is used to help prevent these effects.

Q: Can children use Hydrocortison Jelfa?

Official safety warnings indicate that the use of this medicine in children requires caution and close monitoring. This is because prolonged systemic use carries a risk of growth retardation and developmental issues.

The potential risks mean that prolonged use in this population is generally restricted or requires specific oversight.

Q: What should I do if Hydrocortison Jelfa gets in my eyes?

Safety information for accidental exposure generally recommends flushing the eyes immediately with clear running water for at least 15 minutes.

Safety data suggests that medical attention should be sought if irritation or discomfort persists after rinsing.

Q: What is the difference between Hydrocortison Jelfa cream and ointment?

The difference lies in the base, or vehicle, of the medicine. Regulatory compendiums indicate that ointments are generally thicker and occlusive, making them preferred for dry, scaly skin lesions.

Creams are lighter and are typically used for skin areas that are moist or weeping.

Q: Why is this medication called 'Jelfa'?

The name 'Jelfa' refers to the company Jelfa S.A. (or its affiliated entity), which is the manufacturer or brand name of the drug preparation.

The active ingredient itself is hydrocortisone, which is chemically identical to the natural hormone cortisol.

Q: Can I use other creams or lotions at the same time as Hydrocortison Jelfa?

Official product information cautions that using other topical products simultaneously may affect the absorption of hydrocortisone through the skin.

This change in absorption is noted as a reason for caution regarding the medicine’s potential systemic effects.

Q: What is the key evidence or research theme supporting the use of Hydrocortison Jelfa?

Studies and research themes support its use in two main areas. These are as hormone replacement therapy for conditions where the body lacks natural cortisol, and in studies examining its role in managing severe inflammatory conditions like septic shock.

Q: Are there any long-term consequences described in official documents for Hydrocortison Jelfa use?

Official safety documents state that long-term exposure is associated with several potential consequences.

These include an increased risk of specific ocular effects, such as glaucoma and posterior subcapsular cataracts, as well as conditions like osteoporosis and the development of Cushingoid features.

Q: Is Hydrocortison Jelfa used for joint pain?

Systemic hydrocortisone is officially indicated for the management of various rheumatic and arthritic disorders.

Since these conditions often involve joint inflammation, the medicine is used to help manage the associated symptoms.

Q: Can Hydrocortison Jelfa be used for allergic reactions?

Yes, systemic hydrocortisone is officially listed in regulatory documents for the treatment of certain medical conditions, including managing symptoms associated with severe allergic reactions.

This is due to its potent role in controlling the body's immune and inflammatory responses.

Q: How quickly does Hydrocortison Jelfa typically start working?

The medicine's action involves complex binding to intracellular receptors to modulate gene transcription (the process of making proteins).

This is described as a genomic mechanism that typically requires time to achieve its full effect, rather than having an immediate impact.

Q: Does Hydrocortison Jelfa cause thinning of the skin?

Skin atrophy (thinning) is officially described in regulatory compendiums as a common effect of the overuse or misuse of topical steroids.

Regulatory documents indicate that the risk of this effect is generally related to the potency, duration, and frequency of use.

Q: Is it normal to feel a slight stinging when applying Hydrocortison Jelfa?

Yes, official adverse event profiles describe burning and stinging sensations after application as among the most common effects associated with topical hydrocortisone.

This is usually mild and temporary.

Q: What is the difference between hydrocortisone acetate and the type in Hydrocortison Jelfa?

Hydrocortisone is the biologically active substance. Official studies indicate that the acetate form requires conversion by the body's enzymes to become the active drug.

This difference in metabolism has been examined for its impact on patient metabolic profiles.

Q: Can Hydrocortison Jelfa be used on the face?

Official labeling includes specific warnings for use on the face. This is because the skin on the face is thinner, leading to increased absorption and a higher risk of side effects like skin atrophy.

Its use is also contraindicated (not allowed) in the presence of certain facial conditions like rosacea.

Q: Why do official documents mention 'suppression' when talking about Hydrocortison Jelfa?

'Suppression' refers to the medicine's effect on the Hypothalamic-Pituitary-Adrenal (HPA) axis, which is the system that naturally controls the body's cortisol production.

Official documents highlight this as a safety concern because the medicine can interfere with this natural process, especially if treatment is stopped abruptly.

Q: Can Hydrocortison Jelfa make my skin lighter?

Regulatory lists of adverse effects associated with the drug's use include reports of both darkening or lightening of skin color as a possible reaction.

This is one of the skin changes that may be observed.

Q: Is Hydrocortison Jelfa safe for people with liver or kidney issues?

Official warnings state that caution is mandatory for patients with hepatic impairment (liver issues) due to reduced clearance of the drug.

Caution is also noted for use in patients with renal impairment (kidney issues) due to the potential for effects on fluid and electrolyte balance.

Q: Can using Hydrocortison Jelfa make my condition worse?

Yes, official warnings state that caution is required because the medication may exacerbate (make worse) certain existing medical conditions.

These conditions include, but are not limited to, diabetes mellitus, hypertension, or osteoporosis.

Q: Does Hydrocortison Jelfa help with redness and swelling?

Yes, the core purpose of the medicine is to exert potent anti-inflammatory effects, which is supported by pharmacological studies.

This anti-inflammatory action works to alleviate common symptoms associated with excessive inflammation, such as redness and swelling.

Q: Why is Hydrocortison Jelfa sometimes prescribed for conditions that don't seem like skin issues?

This is because the drug is used systemically (taken orally or by injection), not just on the skin. Its potent anti-inflammatory effects help manage various conditions inside the body, such as rheumatoid arthritis, inflammatory bowel diseases, and certain lung conditions.

Q: Are there different brand names for the same active ingredient as Hydrocortison Jelfa?

Yes, the active ingredient, hydrocortisone, is widely available under multiple brand names (for example, Cortef) in different countries.

It is also commonly available as a generic medication worldwide.

Q: Does Hydrocortison Jelfa interact with herbal remedies?

Official caution is advised regarding herbal remedies. This is because regulators state there is not enough official information to confirm that specific herbal remedies are safe to take with the medicine, as their interactions are often not tested.

Q: Is Hydrocortison Jelfa for treating the cause or just the symptoms?

In its role as an anti-inflammatory and immunosuppressive agent, its primary action is to alleviate symptoms like inflammation and swelling.

It achieves this by suppressing the release of inflammatory substances in the body, rather than targeting the underlying cause of the condition.

How should Hydrocortison Jelfa be stored and disposed of?

Storage and Disposal of Hydrocortison Jelfa

Official regulatory guidelines mandate specific conditions to ensure the stability of hydrocortisone, the active ingredient. The medication must generally be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from freezing, heat, and excessive moisture. Certain tablet formulations require storage in the original blister to protect them from light.

All forms must be stored out of the sight and reach of children. Any unused or expired Hydrocortison Jelfa must be disposed of in accordance with local requirements for pharmaceutical waste. The medication should not be discarded via wastewater or household trash, as instructed by regulatory bodies.

Hydrocortison Jelfa